(NASDAQ: ELTX) Elicio Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 26.44%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.98%.
Elicio Therapeutics's earnings in 2025 is -$51,280,000.On average, 4 Wall Street analysts forecast ELTX's earnings for 2025 to be -$43,892,503, with the lowest ELTX earnings forecast at -$42,171,228, and the highest ELTX earnings forecast at -$45,183,459. On average, 4 Wall Street analysts forecast ELTX's earnings for 2026 to be -$29,941,540, with the lowest ELTX earnings forecast at -$38,722,280, and the highest ELTX earnings forecast at -$20,156,190.
In 2027, ELTX is forecast to generate -$20,069,806 in earnings, with the lowest earnings forecast at -$19,282,755 and the highest earnings forecast at -$20,660,095.